Silverback Therapeutics (SBTX) News Today $14.88 0.00 (0.00%) As of 04/17/2025 Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Silverback Therapeutics (NASDAQ:SBTX) Shares Down 0.7% - Here's WhySilverback Therapeutics (NASDAQ:SBTX) Trading Down 0.7% - Should You Sell?April 20 at 2:52 AM | marketbeat.comSilverback Therapeutics (NASDAQ:SBTX) Shares Down 0.7% - Here's What HappenedApril 18 at 2:55 AM | americanbankingnews.comSilverback Therapeutics (NASDAQ:SBTX) Stock Price Up 2% - Here's WhySilverback Therapeutics (NASDAQ:SBTX) Trading 2% Higher - What's Next?March 27, 2025 | marketbeat.comSilverback Therapeutics (NASDAQ:SBTX) Shares Down 2.9% - Here's What HappenedSilverback Therapeutics (NASDAQ:SBTX) Stock Price Down 2.9% - Here's What HappenedMarch 5, 2025 | marketbeat.comSilverback Therapeutics (NASDAQ:SBTX) Stock Price Down 6.9% - Here's WhySilverback Therapeutics (NASDAQ:SBTX) Shares Down 6.9% - Time to Sell?February 11, 2025 | marketbeat.comSilverback Therapeutics (NASDAQ:SBTX) Trading Down 2%Silverback Therapeutics (NASDAQ:SBTX) Stock Price Down 2%April 3, 2024 | marketbeat.comRoyce & Associates LP Invests $1.98 Million in Silverback Therapeutics, Inc. (NASDAQ:SBTX)Royce & Associates LP bought a new position in shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 303,900 shares of the company's stock, valuedSeptember 13, 2023 | marketbeat.comSR One Capital Management LP Purchases 1,003,226 Shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX)SR One Capital Management LP lifted its stake in shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX - Free Report) by 33.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,012,903 shares of the compAugust 11, 2023 | marketbeat.comLevin Capital Strategies L.P. Boosts Stake in Silverback Therapeutics, Inc. (NASDAQ:SBTX)Levin Capital Strategies L.P. raised its position in Silverback Therapeutics, Inc. (NASDAQ:SBTX - Free Report) by 259.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 140,351 shares of the company'sJuly 7, 2023 | marketbeat.comVontobel Holding Ltd. Raises Holdings in Silverback Therapeutics, Inc. (NASDAQ:SBTX)Vontobel Holding Ltd. grew its position in Silverback Therapeutics, Inc. (NASDAQ:SBTX - Free Report) by 16.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 169,732 shares of the company's stock after buying an additional 23,8June 29, 2023 | marketbeat.comCitigroup Inc. Boosts Stock Holdings in Silverback Therapeutics, Inc. (NASDAQ:SBTX)Citigroup Inc. increased its position in shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) by 22,630.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 95,014 shares of the company's stockJune 2, 2023 | marketbeat.comSilverback Therapeutics, Inc. (NASDAQ:SBTX) Shares Sold by K2 Principal Fund L.P.K2 Principal Fund L.P. cut its stake in Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) by 11.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,872,148 shares of the company's stock after selling 375,385 sharesMay 26, 2023 | marketbeat.comARS Pharmaceuticals Inc (SPRY)May 11, 2023 | uk.investing.comErgoteles LLC Has $394,000 Stock Position in Silverback Therapeutics, Inc. (NASDAQ:SBTX)Ergoteles LLC decreased its stake in shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) by 22.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 74,544 shares of the company's stock after selling 21,756 shMarch 3, 2023 | marketbeat.comRubric Capital Management LP Has $14.23 Million Stock Position in Silverback Therapeutics, Inc. (NASDAQ:SBTX)Rubric Capital Management LP lifted its position in Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) by 173.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,695,170 shares of the company's stock after buyingFebruary 17, 2023 | marketbeat.comSPRY ARS Pharmaceuticals, Inc.January 24, 2023 | seekingalpha.comARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After MergerNovember 22, 2022 | 247wallst.comDr. Sarina Tanimoto Discloses Position in SBTX / Silverback TherapeuticsNovember 18, 2022 | nasdaq.comARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNovember 10, 2022 | finance.yahoo.comARS Pharmaceuticals Closes Merger with Silverback TherapeuticsNovember 8, 2022 | finance.yahoo.comSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic ReactionsOctober 28, 2022 | markets.businessinsider.comSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including AnaphylaxisOctober 21, 2022 | finance.yahoo.comSilverback Therapeutics, Inc. (NASDAQ:SBTX) Short Interest Up 83.5% in SeptemberSilverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) was the recipient of a significant increase in short interest in September. As of September 30th, there was short interest totalling 996,600 shares, an increase of 83.5% from the September 15th total of 543,000 shares. Approximately 4.1% of the shares of the company are short sold. Based on an average trading volume of 277,600 shares, the short-interest ratio is currently 3.6 days.October 14, 2022 | marketbeat.comINVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBTSeptember 17, 2022 | markets.businessinsider.comSBTX Silverback Therapeutics, Inc.September 15, 2022 | seekingalpha.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBTSeptember 6, 2022 | markets.businessinsider.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYAugust 23, 2022 | markets.businessinsider.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTXAugust 17, 2022 | apnews.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTXAugust 11, 2022 | apnews.comSilverback Therapeutics, Inc. (NASDAQ:SBTX) Sees Significant Decrease in Short InterestSilverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) was the recipient of a large decrease in short interest in July. As of July 15th, there was short interest totalling 553,900 shares, a decrease of 28.2% from the June 30th total of 771,200 shares. Currently, 2.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 424,300 shares, the days-to-cover ratio is currently 1.3 days.July 31, 2022 | marketbeat.comSHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing InvestigationsJuly 30, 2022 | morningstar.comINVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYJuly 28, 2022 | apnews.comShareholder Alert - The M&A Class Action Firm Announces the Investigation of Silverback Therapeutics, Inc. - SBTXJuly 27, 2022 | benzinga.comLifshitz Law PLLC Announces Investigation of IEA, ZY, SBTX, and HNGRJuly 26, 2022 | apnews.comSilverback Therapeutics plans merger with San Diego biotechJuly 26, 2022 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HNGR, SBTX, UJuly 25, 2022 | apnews.comSILVERBACK THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of SBTX and Encourages Investors to Contact the FirmJuly 22, 2022 | benzinga.comSHAREHOLDER ALERT: Weiss Law Investigates Silverback Therapeutics, Inc.July 22, 2022 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HNGR, ONEM, SBTX, ZENJuly 22, 2022 | apnews.comOnce A Cancer Company, Silverback Merges With Small Biotech Working On Allergy TreatmentJuly 22, 2022 | finance.yahoo.comSilverback Therapeutics Shares Down After Merger NewsJuly 22, 2022 | marketwatch.comSilverback Therapeutics to merge with San Diego biotech company developing EpiPen alternativeJuly 22, 2022 | msn.comSBTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Silverback Therapeutics, Inc. Is Fair to ShareholdersJuly 21, 2022 | benzinga.comSilverback Therapeutics and ARS Pharmaceuticals Announce MergerJuly 21, 2022 | finance.yahoo.comSilverback Therapeutics, Inc. (NASDAQ:SBTX) Short Interest Down 32.4% in JuneSilverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) saw a large decline in short interest in June. As of June 30th, there was short interest totalling 771,200 shares, a decline of 32.4% from the June 15th total of 1,140,000 shares. Based on an average daily volume of 418,300 shares, the days-to-cover ratio is presently 1.8 days. Currently, 3.2% of the shares of the company are short sold.July 17, 2022 | marketbeat.comWhat You Need To Know About Silverback Therapeutics, Inc.'s (NASDAQ:SBTX) Investor CompositionJune 22, 2022 | finance.yahoo.comSilverback Therapeutics, Inc. (NASDAQ:SBTX) Short Interest Down 16.5% in MaySilverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) saw a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 1,060,000 shares, a decrease of 16.5% from the May 15th total of 1,270,000 shares. Based on an average daily volume of 407,000 shares, the short-interest ratio is presently 2.6 days. Approximately 5.2% of the company's shares are short sold.June 17, 2022 | marketbeat.comSilverback Therapeutics (NASDAQ:SBTX) Stock Rating Lowered by Zacks Investment ResearchZacks Investment Research lowered Silverback Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday.June 1, 2022 | marketbeat.comSilverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceMay 17, 2022 | finance.yahoo.comSilverback Therapeutics, Inc. (NASDAQ:SBTX) Short Interest Up 35.2% in AprilSilverback Therapeutics, Inc. (NASDAQ:SBTX - Get Rating) was the recipient of a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 1,210,000 shares, an increase of 35.2% from the April 15th total of 895,100 shares. Based on an average daily volume of 387,900 shares, the short-interest ratio is presently 3.1 days. Currently, 5.9% of the shares of the company are sold short.May 16, 2022 | marketbeat.com Get Silverback Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address SBTX Media Mentions By Week SBTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SBTX News Sentiment▼0.670.59▲Average Medical News Sentiment SBTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SBTX Articles This Week▼20▲SBTX Articles Average Week Get Silverback Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MIRM News SDGR News MTSR News BHVN News BLTE News NAMS News SUPN News JANX News ARWR News HRMY News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SBTX) was last updated on 4/21/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silverback Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silverback Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
